Published Year: 2018
Global Injectable Drug Delivery Market : Focus on Devices, Competitive Landscape and Country - Analy
The global injectable drug delivery market was estimated at $16.73 billion in 2016 and is...
Market Research Report
A quick peek into the report
Table of Contents
1.1 Inclusion and Exclusion Criteria
1.1.1 Inclusions
1.1.2 Exclusions
2.1 Key Questions Answered in the Report
3.1 Autoimmune Disorder Drug Delivery Devices Market: Research Methodology
3.2 Primary Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling
4.1 Historic Overview and Future Scope of Injectable Drug Delivery Devices
4.2 Pre-Filled Syringes Manufacturing and Packaging Challenges
4.3 Global Autoimmune Disorder Drug Delivery Devices Market and Growth Potential, 2019-2030
4.4 Pricing and Reimbursement Scenario
4.5 Impact of Patent Expiry and Entry of Biosimilars on Autoimmune Disorder Drug Delivery Devices Market
4.6 Impact of COVID-19 on Autoimmune Disorder Drug Delivery Devices Market
5.1 Overview
5.2 Legal Requirements and Frameworks Across the Globe
5.3 Regulatory Framework and Government Initiatives
5.4 Legal Requirements and Frameworks in North America
5.4.1 Food and Drug Administration (FDA)
5.4.2 Health Canada
5.5 Legal Requirements and Frameworks in Europe
5.5.1 European Union
5.6 Legal Requirements and Frameworks in Asia-Pacific
5.6.1 National Medical Products Administration (NMPA)
5.6.2 Pharmaceutical and Medical Device Agency (PMDA)
5.6.3 Central Drug Standard Control Organization (CDSCO)
6.1 Patent Analysis (by Drug Delivery Devices)
6.2 Patent Analysis (by IPC Code)
6.3 Patent Analysis (by Country)
6.4 Patent Analysis (by Company)
7.1 Overview
7.2 Impact Analysis
7.3 Drivers
7.3.1 Increased Prevalence of Autoimmune Disorders
7.3.2 Technological Advancements in the Field of Pre-Filled Syringes
7.3.3 Rising Geriatric Population
7.3.4 Surge of Biosimilars and Biologics in the Pharmaceutical Market
7.3.5 Device Connectivity to Ease Competitive Pressure
7.4 Restraints
7.4.1 Strict Legal Requirements and Regulations
7.4.2 Alternative Drug Delivery Technology
7.5 Opportunities
7.5.1 Providing Injectable Drug Delivery Devices for Untapped Autoimmune Disorders
7.5.2 Opportunities for Personalizing Treatments in Autoimmune Diseases
8.1 Rheumatoid Arthritis
8.2 Psoriasis
8.3 Multiple Sclerosis
8.4 Inflammatory Bowel Diseases
8.5 Systemic Lupus Erythematosus
9.1 Introduction
9.2 Pen Injectors
9.3 Auto-Injectors
9.4 Pre-filled Syringes
9.5 Vials
10.1 In-House Manufacturing
10.2 Outsourced Manufacturing
11.1 Overview
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 U.K.
11.3.3 France
11.3.4 Italy
11.3.5 Spain
11.3.6 Rest-of-Europe
11.4 Asia-Pacific
11.4.1 China
11.4.2 Japan
11.4.3 India
11.4.4 South Korea
11.4.5 Australia
11.4.6 Rest-of-APAC
11.5 Latin America
11.5.1 Brazil
11.5.2 Mexico
11.5.3 Rest-of-Latin America
11.6 Rest-of-the-World
12.1 Key Developments and Strategies
12.1.1 Regulatory and Legal Developments
12.1.2 Partnerships, Alliances, and Business Expansions
12.1.3 Mergers and Acquisitions
12.2 Market Share Analysis
13.1 Overview
13.2 Amgen Inc.
13.2.1 Company Overview
13.2.2 Role of Amgen Inc. in Global Autoimmune Disorder Drug Delivery Devices Market
13.2.3 Financials
13.2.4 Key Insights about Financial Health of the Company
13.2.5 SWOT Analysis
13.3 AbbVie Inc.
13.3.1 Company Overview
13.3.2 Role of AbbVie Inc. in Global Autoimmune Disorder Drug Delivery Devices Market
13.3.3 Financials
13.3.4 Key Insights about Financial Health of the Company
13.3.5 SWOT Analysis
13.4 Bayer AG
13.4.1 Company Overview
13.4.2 Role of Bayer AG in Global Autoimmune Disorder Drug Delivery Devices Market
13.4.3 Financials
13.4.4 Key Insight about Financial Health of the Company
13.4.5 SWOT Analysis
13.5 Biogen Inc.
13.5.1 Company Overview
13.5.2 Role of Biogen Inc. in Global Autoimmune Disorder Drug Delivery Devices Market
13.5.3 Financials
13.5.4 Key Insights about Financial Health of the Company
13.5.5 SWOT Analysis
13.6 Bristol-Myers Squibb Company
13.6.1 Company Overview
13.6.2 Role of Bristol Myers Squibb Company in the Global Autoimmune Disorder Drug Delivery Devices Market
13.6.3 Financials
13.6.4 Key Insights About Financial Health of the Company
13.6.5 SWOT Analysis
13.7 Eli Lilly & Company
13.7.1 Company Overview
13.7.2 Role of Eli Lilly & Company in Global Autoimmune Disorder Drug Delivery Device Market
13.7.3 Financials
13.7.4 Key Insights About Financial Health of the Company
13.7.5 SWOT Analysis
13.8 F. Hoffmann-La Roche Ltd
13.8.1 Company Overview
13.8.2 Role of F. Hoffmann-La Roche Ltd. in Global Autoimmune Disorder Drug Delivery Devices Market
13.8.3 Financials
13.8.4 Key Insights About Financial Health of the Company
13.8.5 SWOT Analysis
13.9 GlaxoSmithKline plc
13.9.1 Company Overview
13.9.2 Role of GlaxoSmithKline plc in Global Autoimmune Disorder Drug Delivery Devices Market
13.9.3 Financials
13.9.4 Key Insights About Financial Health of the Company
13.9.5 SWOT Analysis
13.10 Johnson & Johnson Services, Inc.
13.10.1 Company Overview
13.10.2 Role of Johnson & Johnson Services, Inc. in Global Autoimmune Disorder Drug Delivery Devices Market
13.10.3 Financials
13.10.4 Key Insights About Financial Health of the Company
13.10.5 SWOT Analysis
13.11 Merck KGaA
13.11.1 Company Overview
13.11.2 Role of Merck KGaA in Global Autoimmune Disorder Drug Delivery Devices Market
13.11.3 Financials
13.11.4 Key Insights About Financial Health of the Company
13.11.5 SWOT Analysis
13.12 Novartis AG
13.12.1 Company overview
13.12.2 Role of Novartis AG in Global Autoimmune Disorder Drug Delivery Devices Market
13.12.3 Financials
13.12.4 Key Insights About Financial Health of the Company
13.12.5 SWOT Analysis
13.13 Sanofi S.A.
13.13.1 Company Overview
13.13.2 Role of Sanofi S.A. in Global Autoimmune Disorder Drug Delivery Devices Market
13.13.3 Financials
13.13.4 Key Insights About Financial Health of the Company
13.13.5 SWOT Analysis
13.14 Teva Pharmaceutical Industries Ltd.
13.14.1 Company Overview
13.14.2 Role of Teva Pharmaceutical Industries Ltd. in Global Autoimmune Disorder Drug Delivery Devices Market
13.14.3 Financials
13.14.4 Key Insight About Financial Health of the Company
13.14.5 SWOT Analysis
13.15 UCB Pharma SA.
13.15.1 Company Overview
13.15.2 Role of UCB Pharma SA in Global Autoimmune Disorder Drug Delivery Devices Market
13.15.3 Financials
13.15.4 Key Insight About Financial Health of the Company
13.15.5 SWOT Analysis
Table 1: Leading Players in Global Autoimmune Disorder Drug Delivery Devices Market
Table 4.1: Patent Expiry of Autoimmune Disorder Therapeutics
Table 5.1: Legal Requirements and Frameworks Across the Globe
Table 7.1: Deaths Due to Multiple Sclerosis in Key Countries, 2015-2017
Table 7.2: Filing Requirements for Pre-filled Syringes:
Table 7.3: Differentiation of an Injectable Therapeutic Throughout its Life Cycle:
Table 7.4: Alternative Drug Delivery Technologies:
Table 8.1: Global Autoimmune Disorder Therapeutics Sales, 2017-2019
Figure 1: Global Prevalence of Rheumatoid Arthritis (1990-2017)
Figure 2: Global Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 3: Impact Analysis
Figure 4: Share of Key Developments and Strategies, (September 2017-September 2020)
Figure 5: Global Autoimmune Disorder Drug Delivery Devices Market (by Product), ($Million), 2019 and 2030
Figure 6: Global Autoimmune Disorder Drug Delivery Devices Market (by Indication), ($Million), 2019 and 2030
Figure 7: Global Autoimmune Disorder Drug Delivery Devices Market (by Manufacturing Type), ($Million), 2019 and 2030
Figure 8: Global Autoimmune Disorder Drug Delivery Devices Market (by Region), ($Million), 2019-2030
Figure 2.1: Global Autoimmune Disorders Drug Delivery Devices Market Segmentation
Figure 3.1: Global Autoimmune Disorder Drug Delivery Devices Market Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Key Milestones in History of Syringes
Figure 4.2: Advancements in Injectable Drug Delivery Technology
Figure 4.3: Global Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 5.1: Global Autoimmune Disorder Drug Delivery Devices Market: Regulatory Landscape
Figure 5.2: FDA 510(k) Approval Timeline
Figure 5.3: Health Canada Class II-Medical Device Approval Process
Figure 5.4: European Commission Class IIa-Medical Device Approval Process
Figure 5.5: National Medical Products Administration Class III-Medical Device Approval Process
Figure 5.6: Pharmaceutical and Medical Devices Agency (PMDA) Class II-Medical Device Approval Process
Figure 5.7: Central Drug Standard Control Organization (CDSCO) Class B-Medical Device Approval Process
Figure 6.1: Number of Patents Filed, Autoimmune Disorders Drug Delivery Devices, January 2017-December 2019
Figure 6.2: Patent Analysis (by IPC Code)
Figure 6.3: Patent Analysis (by Country)
Figure 6.4: Patent Analysis (by Company)
Figure 7.1: Impact Analysis
Figure 7.2: Global Prevalence of Rheumatoid Arthritis (1990-2017)
Figure 7.3: Technological Advancements in Pre-Filled Syringes Over Time
Figure 7.4: Global Geriatric Population (by Age)
Figure 7.5: Analysis of Origin of Drugs to Treat Autoimmune Disorders
Figure 7.6: Opportunity Areas for Injectable Drug Delivery Devices
Figure 8.1: Global Autoimmune Disorder Drug Delivery Devices Market, by Indication
Figure 8.2: Global Autoimmune Disorder Drug Delivery Devices Market (by Indication), ($Million), 2019 and 2030
Figure 8.3: Global Autoimmune Disorder Drug Delivery Devices Market (by Rheumatoid Arthritis), ($Million), 2019-2030
Figure 8.4: Rheumatoid Arthritis Drug Delivery Devices Market (By Therapeutics), ($Million), 2017-2019
Figure 8.5: Global Autoimmune Disorder Drug Delivery Devices Market (by Psoriasis), ($Million), 2019-2030
Figure 8.6: Psoriasis Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
Figure 8.7: Global Autoimmune Disorder Drug Delivery Devices Market (by Multiple Sclerosis), ($Million), 2019-2030
Figure 8.8: Multiple Sclerosis Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
Figure 8.9: Global Autoimmune Disorder Drug Delivery Devices Market (by Inflammatory Bowel Diseases), ($Million), 2019-2030
Figure 8.10: Inflammatory Bowel Diseases Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
Figure 8.11: Global Autoimmune Disorder Drug Delivery Devices Market (Systemic Lupus Erythematosus), ($Million), 2019-2030
Figure 8.12: Systemic Lupus Erythematosus Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
Figure 9.1: Revenue Contribution of Different Products, 2019 and 2030
Figure 9.2: Global Autoimmune Disorder Drug Delivery Devices Market (Pen Injectors), ($Million), 2019-2030
Figure 9.3: Pen Injector based Autoimmune Disorder Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
Figure 9.4: Global Autoimmune Disorder Drug Delivery Devices Market (Auto-injectors), ($Million), 2019-2030
Figure 9.5: Auto-Injector based Autoimmune Disorder Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
Figure 9.6: Global Autoimmune Disorder Drug Delivery Devices Market (Pre-filled Syringes), ($Million), 2019-2030
Figure 9.7: Pre-filled Syringes based Autoimmune Disorder Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
Figure 9.8: Global Autoimmune Disorder Drug Delivery Devices Market (Vials), ($Million), 2019-2030
Figure 9.9: Vials based Autoimmune Disorder Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
Figure 10.1: Global Autoimmune Disorder Drug Delivery Devices Market (by Manufacturing Type), ($Million), 2019 and 2030
Figure 10.2: Global Autoimmune Disorder Drug Delivery Devices Market (by In-house Manufacturing), ($Million), 2019-2030
Figure 10.3: Global Autoimmune Disorder Drug Delivery Devices Market (by Outsourced Manufacturing), ($Million), 2019-2030
Figure 11.1: Global Autoimmune Disorder Drug Delivery Devices Market (by Region)
Figure 11.2: Global Autoimmune Disorder Drug Delivery Devices Market (by Region), ($Million), 2019-2030
Figure 11.3: North America Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.4: North America: Market Dynamics
Figure 11.5: Revenue Contributions of Different Countries in North America, ($Million), 2019 and 2030
Figure 11.6: U.S. Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.7: Canada Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.8: Europe Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.9: Europe: Market Dynamics
Figure 11.10: Revenue Contributions Different Countries in Europe, ($Million), 2019 and 2030
Figure 11.11: Germany Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.12: U.K. Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.13: France Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.14: Italy Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.15: Spain Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.16: Rest-of-Europe Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.17: Asia-Pacific Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.18: APAC: Market Dynamics
Figure 11.19: Revenue Contributions Different Countries in Asia-Pacific, ($Million), 2019 and 2030
Figure 11.20: China Autoimmune Disorder Drug Delivery Devices market, ($Million), 2019-2030
Figure 11.21: Japan Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.22: India Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.23: South Korea Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.24: Australia Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.25: RoAPAC Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.26: Latin America Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.27: Latin America: Market Dynamics
Figure 11.28: Revenue Contributions of Different Countries in Latin America, ($Million), 2019 and 2030
Figure 11.29: Brazil Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.30: Mexico Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.31: Rest-of-Latin America Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.32: RoW Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 12.1: Share of Key Developments and Strategies, September 2017-September 2020
Figure 12.2: Regulatory and Legal Developments Share (by Company), September 2017- September 2020
Figure 12.3: Partnerships, Alliances, and Business Expansions (by Company), September 2017-September 2020
Figure 12.4: Mergers and Acquisitions Share (by Company), September 2017-September 2020
Figure 12.5: Market Share Analysis (by Companies), 2018 and 2019
Figure 13.1: Total Number of Companies Profiled
Figure 13.2: Amgen Inc.: Overall Product Portfolio
Figure 13.3: Amgen Inc.: Overall Financials, 2017-2019
Figure 13.4: Amgen Inc.: Revenue (by Region), 2017-2019
Figure 13.5: Amgen Inc.: R&D Expenditure, 2017-2019
Figure 13.6: Amgen Inc.: SWOT Analysis
Figure 13.7: AbbVie Inc.: Overall Product Portfolio
Figure 13.8: AbbVie Inc.: Overall Financials, 2017-2019
Figure 13.9: AbbVie Inc.: Revenue (by Region), 2017-2019
Figure 13.10: AbbVie Inc.: R&D Expenditure, 2017-2019
Figure 13.11: AbbVie Inc.: SWOT Analysis
Figure 13.12: Bayer AG: Overall Product Portfolio
Figure 13.13: Bayer AG: Overall Financials, 2017-2019
Figure 13.14: Bayer AG: Revenue (by Segment), 2018-2019
Figure 13.15: Bayer AG: Revenue (by Region), 2017-2019
Figure 13.16: Bayer AG: R&D Expenditure, 2017-2019
Figure 13.17: Bayer AG: SWOT Analysis
Figure 13.18: Biogen Inc.: Overall Service Portfolio
Figure 13.19: Biogen Inc.: Overall Financials, 2017-2019
Figure 13.20: Biogen Inc.: Sales (by Product), 2017-2019
Figure 13.21: Biogen Inc.: Sales (by Region), 2017-2019
Figure 13.22: Biogen Inc.: R&D Expenditure, 2017-2019
Figure 13.23: Biogen Inc.: SWOT Analysis
Figure 13.24: Bristol Myers Squibb Company: Overall Product Portfolio
Figure 13.25: Bristol Myers Squibb Company: Overall Financials, 2017-2019
Figure 13.26: Bristol Myers Squibb Company: Revenue (by Region), 2017-2019
Figure 13.27: Bristol Myers Squibb Company: R&D Expenditure, 2017-2019
Figure 13.28: Bristol Myers Squibb Company: SWOT Analysis
Figure 13.29: Eli Lilly & Company: Product Portfolio
Figure 13.30: Eli Lilly & Company: Pipeline Product Portfolio
Figure 13.31: Eli Lilly & Company: Overall Financials, 2017-2019
Figure 13.32: Eli Lilly & Company: Revenue (by Region), 2017-2019
Figure 13.33: Key Insights About Financial Health of the Company
Figure 13.34: Eli Lilly & Company: SWOT Analysis
Figure 13.35: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 13.36: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 13.37: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
Figure 13.38: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
Figure 13.39: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
Figure 13.40: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 13.41: GlaxoSmithKline plc: Pipeline Product Portfolio
Figure 13.42: GlaxoSmithKline plc: Overall Financials, 2017-2019
Figure 13.43: GlaxoSmithKline plc: Revenue (by Segment), 2017-2019
Figure 13.44: GlaxoSmithKline plc: Revenue (by Region), 2017-2019
Figure 13.45: GlaxoSmithKline plc: R&D Expenditure, 2017-2019
Figure 13.46: GlaxoSmithKline plc: SWOT Analysis
Figure 13.47: Johnson & Jonson Services, Inc.: Product Portfolio
Figure 13.48: Johnson & Jonson Services, Inc.: Pipeline Products Portfolio
Figure 13.49: Johnson & Johnson Services, Inc. Company: Overall Financials, 2017-2019
Figure 13.50: Johnson & Johnson Services, Inc. Company: R&D Expenditure, 2017-2019
Figure 13.51: Johnson & Johnson Services, Inc.: SWOT Analysis
Figure 13.52: Merck KGaA: Product Portfolio
Figure 13.53: Merck KGaA: Overall Financials, 2017-2019
Figure 13.54: Merck KGaA: Revenue (by Segment), 2017-2019
Figure 13.55: Merck KGaA: Revenue (by Region), 2017-2019
Figure 13.56: Merck KGaA: R&D Expenditure, 2017-2019
Figure 13.57: Merck KGaA: SWOT Analysis
Figure 13.58: Novartis AG: Products Portfolio
Figure 13.59: Novartis AG: Pipeline Products Portfolio
Figure 13.60: Novartis AG: Overall Financials, 2017-2019
Figure 13.61: Novartis AG Net Revenue (by Business Segment), 2017-2019
Figure 13.62: Novartis AG: Net Revenue (by Region), 2017-2019
Figure 13.63: Novartis AG: R&D Expense, 2017-2019
Figure 13.64: Novartis AG: SWOT Analysis
Figure 13.65: Sanofi S.A.: Overall Product Portfolio
Figure 13.66: Sanofi S.A.: Overall Financials, 2017-2019
Figure 13.67: Sanofi S.A.: Revenue (by Segment), 2017-2019
Figure 13.68: Sanofi S.A.: Revenue (by Region), 2017-2019
Figure 13.69: Sanofi S.A.: R&D Expenditure, 2017-2019
Figure 13.70: Sanofi S.A.: SWOT Analysis
Figure 13.71: Teva Pharmaceutical Industries Ltd.: Overall Product Portfolio
Figure 13.72: Teva Pharmaceutical Industries Ltd.: Overall Financials, 2017-2019
Figure 13.73: Teva Pharmaceutical Industries Ltd.: Net Revenue (by Business Segment), 2017-2019
Figure 13.74: Teva Pharmaceutical Industries Ltd.: Research and Development Expense, 2017-2019
Figure 13.75: Teva Pharmaceutical Industries Ltd.: SWOT Analysis
Figure 13.76: UCB Pharma SA: Overall Product Portfolio
Figure 13.77: UCB Pharma SA: Overall Product Portfolio
Figure 13.78: UCB Pharma SA: Overall Financials, 2017-2019
Figure 13.79: UCB Pharma SA: Revenue (by Product), 2017-2019
Figure 13.80: UCB Pharma SA: Revenue (by Region), 2017-2019
Figure 13.81: UCB Pharma SA: R&D Expenditure, 2017-2019
Figure 13.82: UCB Pharma SA: SWOT Analysis
Report Description
|
Market Report Coverage - Autoimmune Disorder Drug Delivery Devices |
|||
|
Base Year |
2019 |
Market Size in 2019 |
$1,685.2 Million |
|
Forecast Period |
2020-2030 |
Value Projection and Estimation by 2030 |
$10,686.5 Million |
|
CAGR During Forecast Period |
15.25% |
Number of Tables |
8 |
|
Number of Pages |
247 |
Number of Figures |
176 |
|
Research Hours |
240 |
|
|
|
Market Segmentation |
• Indication – Systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, and psoriasis • Product Type – Pen injectors, auto-injectors, pre-filled syringes, and vials • Manufacturing Type – In-house manufacturing and outsourced manufacturing |
||
|
Regional Segmentation |
• North America – U.S., Canada • Europe – Germany, France, Italy, U.K., Spain, Russia, and Rest-of-Europe • Asia-Pacific – China, Japan, India, Taiwan, South Korea, Singapore, Australia, and Rest-of-Asia-Pacific (RoAPAC) • Latin America – Brazil, Mexico, and Rest-of-the-Latin America • Rest-of-the-World |
||
|
Growth Drivers |
• Increased Prevalence of Autoimmune Disorders • Technological Advancements in the Field of Pre-Filled Syringes • Rising Geriatric Population • Surge of Biosimilars and Biologics in the Pharmaceutical Market • Device Connectivity to Ease Competitive Pressure |
||
|
Market Challenges |
• Strict Legal Requirements and Regulations • Alternative Drug Delivery Technology |
||
|
Market Opportunities |
• Providing Injectable Drug Delivery Devices for Untapped Autoimmune Disorders • Opportunities of Personalizing Treatments in Autoimmune Diseases |
||
|
Key Companies Profiled |
AbbVie Inc., Amgen Inc., F. Hoffmann- La Roche Ltd., Novartis AG, GlaxoSmithKline Plc, Bristol Myers Squibb Company, Biogen Inc., Merck KGaA, Bayer AG, Johnson & Johnson Services Inc., Teva Pharmaceutical Industries Ltd., Eli Lily and Company, Sanofi S.A., UCB Inc., and Takeda Pharmaceutical Company Limited, among others |
||
Key Questions Answered in this Report:
• What are the various autoimmune disorders drug delivery devices available in the market?
• What are emerging drug delivery devices for the treatment of autoimmune disorders?
• How does the pipeline for global autoimmune disorders drug delivery devices market look like?
• What is the current market size and future potential of these drug delivery devices?
• What are the major market drivers, challenges, and opportunities in the global autoimmune disorders drug delivery devices market?
• What is the patent landscape of this market?
• What will be the impact of COVID-19 on this market?
• What are the guidelines implemented by different government bodies to regulate the approval of autoimmune disorders drug delivery devices?
• What are the key technological developments on which the current industry leaders are spending a major share of their research and development (R&D) investments?
• Who are the leading players holding dominating shares in the global autoimmune disorders drug delivery devices market, currently?
• What are the key strategies incorporated by the players of global autoimmune disorders drug delivery devices market, to sustain the competition and retain their supremacy?
• What is the current revenue contribution of the global autoimmune disorders drug delivery devices market (by product type), and how would it evolve in the forecast period?
• What is the current revenue contribution of the global autoimmune disorders drug delivery devices market (by indication), and how would it evolve in the forecast period?
• What is the current revenue contribution of the global autoimmune disorders drug delivery devices market (by route of administration), and how would it evolve in the forecast period?
• What is the current revenue contribution of the global autoimmune disorders drug delivery devices market (by usage type), and how would it evolve in the forecast period?
• What is the current revenue contribution of the global autoimmune disorders drug delivery devices market (by therapeutics), and how would it evolve in the forecast period?
• Which region is expected to contribute to the highest revenue of the global autoimmune disorders drug delivery devices market during the forecast period?
Market Overview
Healthcare experts have found the autoimmune disorders industry to be one of the most rapidly evolving markets. The global market for autoimmune disorder drug delivery devices is predicted to grow at a CAGR of 15.25% over the forecast period of 2020-2030. The market is driven by certain factors, including the increasing global geriatric population, increasing incidence of chronic diseases including autoimmune disorders, and rise in demand for self-injectable systems.
The market is favored by the development of autoimmune disorder drug delivery devices for several clinical areas such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, and psoriasis. The increase in the geriatric population and incurable autoimmune disorders across the globe are expected to translate into a significantly higher demand for autoimmune disorder drug delivery devices.
Furthermore, the companies are investing huge amounts in research and development of autoimmune disorder drug delivery devices. The clinical trial landscape of different autoimmune disorders has been on the rise in recent years, and this will drive the autoimmune disorder drug delivery devices market in the future.
Within the research report, the market is segmented based on indication, product type, manufacturing type, and region. Each of these segments covers the market’s snapshot over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the adoption of self-injection devices for the treatment of autoimmune disorders has created a buzz among companies to invest in the development of novel autoimmune disorder drug delivery devices. Due to the leading market products and intense market penetration, Amgen Inc. has been a pioneer in this field and has been a significant competitor in this market.
Several other companies, such as Novartis AG, F. Hoffmann- La Roche Ltd., and Bristol Myers Squibb Company, have launched drug delivery devices for autoimmune disorders.
Based on region, North America holds the largest share of the autoimmune disorder drug delivery devices market due to improved healthcare infrastructure, rise in per capita income, and availability of state-of-the-art research laboratories and institutions in the region. Apart from this, the Asia-Pacific region is anticipated to grow at a high CAGR during the forecast period.
Global Autoimmune Disorder Drug Delivery Devices Market
Focus on Product Type, Indication, Manufacturing Type, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2030
Some Faq's
Frequently Asked Questions
Answer – From a market value of $1.69 billion in 2019, the global market for autoimmune disorder drug delivery devices is estimated to reach the mark of $10.67 billion by the end of 2030.
Answer – Factors such as the increased prevalence of autoimmune disorders, technological advancements in the field of pre-filled syringes, rising geriatric population, and the surge of biosimilars and biologics in the pharmaceutical market, influence the growth curve of the global autoimmune disorder drug delivery devices market
Answer – The exponential rise in the adoption of self-injection devices for the treatment of autoimmune disorders has created a buss among companies to invest in the development of novel autoimmune disorder drug delivery devices.
Answer – Based on region, the North American region dominates the global market due to its improved healthcare infrastructure, rise in per capita income, and availability of state-of-the-art research laboratories and institutions.
Answer – Prominent market players involved include Amgen Inc., AbbVie Inc., Bayer AG, Biogen Inc., Eli Lilly & Company, GSK PLC, Merck KGaA, and Teva Pharmaceutical Industries Ltd., among others.
Similar Product
You may also like